| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID472030 | AUC (0 to infinity) in rat at 2 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472042 | Inhibition of human ERG current at 1 uM | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472043 | Inhibition of human ERG current | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID459233 | Inhibition of L type calcium channel alpha-1c/alpha-2-delta-1/beta-1b expressed in HEK293 cells in presence of -100 mV holding potential by whole-cell patch clamp method | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
| Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. |
| AID472033 | Apparent oral clearance in rat at 2 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID1391671 | Inhibition of Cav2.2 in human SH-SY5Y cells assessed as decrease in KCl-induced calcium mobilization measured after 600 secs post compound addition and 300 secs post KCl addition in presence of CaV1 blocker nifedipine by calcium 4 dye-based FLIPR assay | 2018 | Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
| Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. |
| AID1391672 | Inhibition of recombinant human Cav3.2-alpha1 expressed in HEK293T cells assessed as decrease in KCl-induced calcium mobilization measured after 600 secs post compound addition and 300 secs post KCl addition by calcium 4 dye-based FLIPR assay | 2018 | Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
| Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. |
| AID472046 | Displacement of radioligand from mu opioid receptor at 10 uM | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472038 | Half life in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472031 | Half life in rat at 2 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472026 | Blocking of rat Voltage-dependent L-type calcium channel alpha1c/alpha2delta-1/beta1b activity expressed in HEK293 cells assessed as whole cell current by whole cell patch clamp assay | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472029 | AUC (0 to 8 hrs) in rat at 2 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472027 | Selectivity ratio of IC50 for rat Voltage-dependent L-type calcium channel to IC50 for rat N-type calcium channel | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472044 | Displacement of radioligand from Voltage-dependent L-type calcium channel at 10 uM | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472037 | AUC (0 to infinity) in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472041 | Analgesic activity against phse 2A portion of rat formalin-induced inflammatory pain model assessed as flinches at 25 mg/kg, ip | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472035 | Tmax in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472045 | Displacement of radioligand from cannabinoid CB1 receptor at 10 uM | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472036 | AUC (0 to 8 hrs) in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472034 | Cmax in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID459237 | Analgesic activity in Sprague-Dawley rat assessed as inhibition of spinal nerve injury-induced thermal hyperalgesia at 30 mg/kg, po after 60-90 mins | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
| Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. |
| AID472032 | Volume of distribution at steady state in rat at 2 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID471769 | Blocking of rat N-type calcium channel alpha-1B/alpha-2-delta-1/beta-1b activity expressed in HEK293 cells assessed as whole cell current by whole cell patch clamp assay | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472040 | Oral bioavailability in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472047 | Displacement of radioligand from voltage-gated sodium channel at 10 uM | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID472039 | Apparent oral clearance in rat at 10 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID459236 | Analgesic activity in Sprague-Dawley rat assessed as inhibition of spinal nerve injury-induced mechanical allodynia at 30 mg/kg, po after 60-90 mins | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
| Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. |
| AID472028 | Cmax in rat at 2 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| AID459232 | Inhibition of N type calcium channel alpha-1b/alpha-2-delta-1/beta-1b expressed in HEK293 cells at holding potential of -100 mV by whole-cell patch clamp method | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
| Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. |
| AID459235 | Aqueous solubility at pH 7.4 | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
| Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. |
| AID1346693 | Rat Cav2.2 (Voltage-gated calcium channels) | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
| Scaffold-based design and synthesis of potent N-type calcium channel blockers. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |